American Conference Institute’s 6th Annual Forum on:

Sunshine Act, Open Payments, and Aggregate Spend Compliance

HCP Reporting Risk Mitigation and Compliance Strategies for Biopharmaceutical and Medical Device Manufacturers

Monday, October 20 to Wednesday, October 22, 2014
The DoubleTree Suites by Hilton Times Square, New York, NY

With Phase 2 reporting now underway and the public release of the Open Payments data slated for fall, companies are now facing new challenges resulting from Sunshine Act compliance, including preparing for the downstream impact of data transparency. Ensure that you are on the same page as your peers and ready to certify with confidence despite the challenges encountered in the first reporting period.

With a focus on benchmarking and improving existing compliance programs as well as preparing for the fallout once the reports are public, this is a solutionsdriven event. Attendees at all phases of aggregate spend implementation will leave this conference with practical tips and real-world tested solutions to better manage the increasingly complex and often unclear reporting requirements. Throughout the event, our expert faculty will provide guidance and solutions for improving compliance protocols to minimize future problems and ensure that you are able to certify with confi dence going forward.

Why this year’s event is a must-attend for you and your team:

  • By October, you will have the benefi t of examining what worked and what didn’t in the fi rst reporting period to prepare for the next round in March 2015. Network and brainstorm with thought leaders from over 20 companies including Abbott, Biomet, Bristol-Myers Squibb Company, DePuy, Eli Lilly and Company, Purdue, Pfizer, Smith & Nephew and many more who will share their experiences to help you meet the intense challenge of satisfying complex federal and state disclosure requirements. Developed by attorneys based on the insights of attorneys and compliance offi cers on the front lines of reporting, every session at this conference has been tailored to be both practical and forward-thinking; unlike other events, this is not a vendor-driven meeting.
  • Prepare for the enforcement consequences and public relations fallout once the database is public in this Fall. Hear directly from multiple sessions of federal and state enforcers about what they will be looking for when combing through the data so that you can strengthen your compliance program in preparation for intense examination by your competitors, relators, and state and federal authorities. Featuring a keynote address regarding CMS’s expectations going forward, you will walk away positioned to certify with confi dence for March
  • Leave the conference poised to meet the massive challenge of satisfying federal, state, and international disclosure requirements in an expedited timeframe and add value to your conference experience by attending the interactive workshops:
  • Pre-Conference Workshop: Comprehensive Analysis of State Disclosure Laws: Preemption, Enforcement, and Continued Reporting Requirements
  • Post-Conference Master Class on Setting Up an International Transparency Program: Risk Mitigation Strategies for Global Spend

Attending this conference will save you time and money as a frontline faculty including CMS, drug and device manufacturers, government enforcers, state legislators, and policy advisors help you formulate real-world, cost-effective strategies to capture and report accurate and compliant spend data. Join your colleagues who are going through this process alongside you by calling 888-224-2480, faxing your registration form to 877-927-1563 or registering online at